...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy) acetamide-based antituberculosis agents
【24h】

Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy) acetamide-based antituberculosis agents

机译:新的2-(喹啉-4-基氧基)乙酰胺基抗尿剂药物的设计,合成和评价

获取原文
获取原文并翻译 | 示例
           

摘要

Using a classical molecular simplification approach, a series of 36 quinolines were synthesized and evaluated as in vitro inhibitors of Mycobacterium tuberculosis (M. tuberculosis) growth. Structure-activity relationship (SAR) studies leaded to potent antitubercular agents, with minimum inhibitory concentration ( MIC) values as low as 0.3 mu M against M. tuberculosis H37Rv reference strain. Furthermore, the lead compounds were active against multidrug-resistant strains, without cross-resistance with some first- and second-line drugs. Testing the molecules against a spontaneous mutant strain containing a single mutation in the qcrB gene (T313A) indicated that the synthesized quinolines targeted the cytochrome bc(1) complex. In addition, leading compounds were devoid of apparent toxicity to HepG2 and Vero cells and showed moderate elimination rates in human liver S9 fractions. Finally, the selected structures inhibited M. tuberculosis growth in a macrophage model of tuberculosis infection. Taken together, these data indicate that this class of compounds may furnish candidates for the future development of antituberculosis drugs. (c) 2020 Published by Elsevier Masson SAS.
机译:使用经典的分子简化方法,合成了一系列36个喹啉,并作为分枝杆菌(结核病)生长的体外抑制剂。结构 - 活性关系(SAR)研究引入有效的抗细胞剂,最小抑制浓度(MIC)值低至M.结核H37RV参考菌株的0.3μm。此外,铅化合物对多药抗性菌株有效,而无抗抗抗抗性和一些第一和二线药物。测试含有QCRB基因(T313A)中单个突变的自发突变菌株的分子表明合成的喹啉靶向细胞色素BC(1)复合物。此外,前导化合物对HepG2和Vero细胞没有表观毒性,并且在人肝S9分数中显示出中度的消除率。最后,所选结构抑制结核感染巨噬细胞模型中的结核病生长。在一起,这些数据表明这类化合物可以为未来发展抗结核药物提供候选人。 (c)2020由Elsevier Masson SA发表。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号